Availability and Use of Vaccines against COVID-19 in Pregnancy

Saugat Koirala1, Smriti Pant2, Binay Kumar Chaudhary3
1Department of Obstetrics and Gynecology, Haamro Sahayatri Hospital, Jadibuti, Kathmandu, Nepal
2Department of Community Medicine, Maharajgunj Medical Campus, Maharajgunj, Kathmandu, Nepal
3Department of General Surgery, Bhaktapur Hospital, Bhaktapur, Nepal

ABSTRACT

Pregnant women when infected with SARS-CoV-2 infection are more at risk of having severe outcomes including ICU admission, adverse cardiac and thromboembolic events and preterm delivery. Immunization in pregnancy has certain ethical dilemmas and vaccination seems to be challenging. Preliminary data regarding the use of mRNA based vaccines against this virus in pregnant women is promising. Recently, RCOG and WHO have widened the scope of use of vaccines among pregnant women against COVID-19. Similarly, ACOG has also given the go-ahead to the use of two mRNA based and one viral vector based vaccine in pregnant women. The scope of vaccination among pregnant and lactating women being realized in developed part of world is a promising prospect in prevention of COVID-19 infections. However, developing nations require attention from private stakeholders, health and social care organizations to ensure right of health for all.

KEY WORDS
Corona Virus, COVID-19, Immunization, Pregnancy, Vaccination

INTRODUCTION

The SARS-CoV-2 (Corona Virus) infection was first identified in 2019 from a pneumonia patient in Wuhan, China and since then has rapidly spread all over the world [1]. Despite efforts in containment and quarantine measures, the infection rates along with morbidity and mortality due to this infection keep soaring [1]. With COVID-19 cases rising in significant proportion, the number of infected pregnant women of all gestational ages has increased rapidly [2].

Pregnant women are found to have severe outcomes with COVID-19 infection compared to non-pregnant women including greater rates of Intensive Care Unit admissions and preterm delivery [3, 4]. Acute respiratory distress syndrome, renal failure, adverse cardiac outcome, thromboembolic events are other complications in those gravid population who get infected with Corona Virus infection [5]. Physiological changes in pregnancy along with immunologic alterations add to the distress in the gravid population when they get infected with this virus [6, 7]. Prevention of such infection with active immunization and prophylaxis is of as much importance if not more than the antiviral therapy [7]. Viral infection triggers hypoxia and inflammation in mothers along with cytokine storm with the release of interleukin-6 and TNF-alpha [8, 9]. There have also been incidences of intrauterine transmission of this infection in the fetus [8, 9]. The hypoxia and inflammation could have an association with adverse perinatal and neonatal outcomes [8]. Yet the issues of vertical transmission of COVID-19 infection and the potential of vaccine use in its prevention lags adequate research [10]. The aim of the article was to study about the availability of COVID-19 vaccine and its use in pregnancy and lactation. This article is one of the first ones to include the latest preliminary findings of the effects of vaccination in the pregnancy and lactation.

METHOD

For writing this Narrative Review article, Google, Google Scholar, Pub Med and online news portals were searched by using various combination of the following terminologies: “COVID-19”, “Corona Virus”, “SARS-CoV-2”, “Pregnancy”, “Lactation”, “Vaccine”, “Vaccination”, “Immunization”, “Pfizer”, “Moderna”, “Janssen”, “Oxford”, “AstraZeneca”, “Newborn”, “CDC”, “FDA”, “ACOG”, “RCOG”, “WHO”, “Findings” and “Outcomes”. We screened all the articles that we found from the search, with the aim of including articles that had information about different types of vaccines against COVID-19 and their use in pregnancy. Next, we acquired the full text of the potential articles and used the articles that met our criteria for writing the review. The duration of writing the article was two months.

*Corresponding Author
Dr. Saugat Koirala, Department of Obstetrics and Gynecology, Haamro Sahayatri Hospital, Jadibuti, Kathmandu, Nepal | Email: saugatkoirala.sk@gmail.com
Vaccination in Pregnancy

Immunization is a known mode to check the spread of vaccine-preventable infectious diseases among pregnant ladies and their newborn [11]. Few inactivated vaccines are available for routine use in pregnancy [11, 12]. However, because of risks of abortion, premature delivery, congenital anomaly and fetal morbidity and mortality; several live attenuated vaccines and other inactivated vaccines are only available for selective use [11, 12]. Routine immunization is administered to all the pregnant women for the prevention against tetanus, diphtheria and pertussis [12, 13]. Apart from those, there are vaccines offered only to the women at high risk of exposure to hepatitis A and B, pneumococcal, meningococcal, typhoid, polio infections while only post-exposure prophylaxis are given for rabies and anthrax [12, 13].

Vaccine Against COVID-19 in Pregnancy and Lactation

Only few SARS-CoV-2 vaccines are available with phase—III results, for example mRNA, viral vector, recombinant antigen and inactivated virus, with high protection rates against this infection [14]. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved only three COVID-19 vaccines for emergency use in which mRNA based are Moderna, BioNTech (Pfizer) while adenoviral vector-based is Ad26.Cov2.S (Janssen) [14-16]. Oxford- AstraZeneca (AZD1222) is a viral vector vaccine which has been approved by EMA and has been used in the citizens of the U.K. [14-16].

Early findings of safety of mRNA Covid-19 vaccine among 35,691 pregnant women in the United States, who had been vaccinated from 14th of December 2020 to 28th of February 2020 are available [17]. This study showed no noticeable issues regarding harm to the health of mother or the fetus/newborn because of immunization with mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna [17]. Among the 827 women who had completed their pregnancy after receiving vaccination, the most common adverse event was spontaneous abortion (12.6 %), which was no higher than the normal population who undergo pregnancy [17]. Other outcomes like stillbirth, preterm birth, small for gestational age and neonatal age were also noted, all of which had occurrence no greater than the general population [17].

In Poland, a retrospective study among 150 pregnant women vaccinated with two doses of BNT162b2 mRNA COVID-19 vaccine had suggested that maternal vaccination could confer newborn safety via trans-placental transference of antibodies [18]. While a case report on a woman who had received BNT162b2 mRNA vaccine had similar result, where trans-placental antibodies for SARS-CoV-2 were found on the newborn [19]. A New York based study done between January and March 2021 in 122 pregnant women who received mRNA vaccine also showed that the transference of trans-placental antibody could be expected in the newborn and that too as soon as 16 days from the administration of the first dose [20].

Another cohort study from Israel had enrolled pregnant women, breastfeeding mother and non-pregnant women between 18 and 45 years age group, from December 2020 to March 2021 for receiving mRNA COVID-19 vaccine (either Moderna or Pfizer-BioNTech) [21]. Among those participants, there were 30 pregnant and 16 lactating women who had received immunization as proposed with no severe complications on pregnancy or the baby [21]. According to this study, the used mRNA vaccines induced protective immune responses against SARS-CoV-2 among all the study population [21].

Guidelines and Recommendation on COVID-19 Vaccines in Pregnancy and Lactation

Despite limited data available about vaccination in pregnant women, Center for Disease Control, USA and FDA in the United States have recently approved for the use of Johnson & Johnson’s Janssen COVID-19 vaccine in pregnancy and lactation [22]. For general population planning to conceive, WHO and CDC have approved the mRNA vaccines, while for pregnant women without comorbidity only Pfizer has proposed for administration of its mRNA vaccine [23]. CDC, EMA, JCVI and Pfizer, however, recommends SARS-CoV-2 vaccination with mRNA vaccination in lactating women [23].

Royal College of Obstetrics and Gynecology (RCOG) has recently published an updated list of the groups of pregnant women who could be offered the Pfizer or Moderna COVID-19 vaccine [24]. This includes pregnant women having higher chances of getting severe COVID-19 infection, health and social care workers with increased risk of catching this infection [24]. Also, women with underlying health conditions, gestational diabetes or women with a BMI of over 40 kg/m2 are eligible for vaccination against Corona Virus [24]. American College of Obstetrics and Gynecology (ACOG) has also recommended the pregnant and lactating women to have access to COVID-19 vaccines, but this includes only afore mentioned vaccines approved by US FDA for emergency use, which includes those manufactured by Moderna, Jannsen and Pfizer (Table 1) [25].

Concerns regarding mild side effects of the COVID-19 vaccine ranges from injection site soreness, lethargy, fever, chills, joint and muscle pain [24, 25]. In patients immunized with AstraZeneca vaccine and Janssen vaccine against COVID-19, serious cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported in general population [24, 25]. Thus, it is logical to say that
Moderna and Pfizer manufactured mRNA vaccines against SARS-CoV-2 for now should be available to pregnant and breastfeeding women throughout the world. There is a pregnancy exposure registry for Moderna, AstraZeneca and Janssen Covid-19 vaccines which are in the process of clinical trial registration for immunization during pregnancy [26, 27]. In most parts of the world, pregnant women have been left off of the clinical trials because of the concerns regarding safety of vaccine in pregnant and lactating mothers and their fetuses and lack of a common consensus of the authorities [28].

INEQUITY IN DISTRIBUTION AND CHALLENGES OF ACCEPTANCE

We should also note that maternal health care facilities, including provision of immunization service, have suffered during this COVID-19 pandemic, especially in developing countries [29]. Many developing nations have to depend on other developed countries for vaccines [30]. Low and middle-income countries have suffered from a collapse of healthcare system in this deadly pandemic and have been deprived of vaccines because of various challenges in receipt, distribution and administration of vaccine. The spread of COVID-19 infections among pregnant women has made it even worse [30, 31]. Even the frontline pregnant workers in many parts of world are yet to be immunized against Corona Virus infection [32]. It is an alarming issue of whether the mutations in the SARS-CoV-2 will lead to lesser effectiveness of available vaccines to the newer variants [33].

Another challenge lies in appropriate and needful counseling in pregnant women with clarity regarding the risks of COVID-19 in pregnancy, available data of the safety and effectiveness of the vaccine and scope of future research [14]. With this comes the issue of acceptance of lactating women globally get vaccinated with mRNA based vaccines.

### TABLE 1 Types of Vaccines and Recommendations for use in Pregnancy and Breastfeeding [14, 23-25]

<table>
<thead>
<tr>
<th>Type of SARS-CoV-2 Vaccine</th>
<th>Manufacturer</th>
<th>Technology</th>
<th>CDC</th>
<th>WHO</th>
<th>Breast feeding</th>
<th>ACOG</th>
<th>RCOG</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA-1273</td>
<td>Pfizer, BioNTech</td>
<td>mRNA</td>
<td>In pregnancy with comorbidities</td>
<td>MBC in women with risk of exposure</td>
<td>R</td>
<td>R</td>
<td>R in high risk cases</td>
</tr>
<tr>
<td>BNT162b2</td>
<td>Moderna Therapeutics</td>
<td>mRNA</td>
<td>In pregnancy with comorbidities</td>
<td>MBC in women with risk of exposure</td>
<td>MBC (WHO)</td>
<td>R</td>
<td>R in high risk cases</td>
</tr>
<tr>
<td>AZD1222</td>
<td>Oxford- AstraZeneca</td>
<td>Viral vector</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ad26.COV2.S</td>
<td>Janssen Pharmaceutica</td>
<td>Viral vector</td>
<td>R</td>
<td>R (CDC)</td>
<td>R</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

R= Recommended, MBC= May be Considered, high risk cases = includes those having high risk of catching infection, high BMI, GDM, health and social care workers
Author Contributions
SK conceptualized the idea, formulated the methodology, wrote the original draft, reviewed and edited the article. SP contributed to formulation of the methodology, reviewed and edited the article. BKC also reviewed and edited the article.

Financial Support
No funding was obtained for writing the article.

Conflict of Interest
Authors declare no conflict of interest.

REFERENCES


23. Dry S, Veiga A, Horton M, Gianaroli L. Joint IFFS/ESHRE statement on COVID-19 vaccination for pregnant women and


